These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 9515799

  • 1. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL.
    Cancer Res; 1998 Mar 15; 58(6):1149-58. PubMed ID: 9515799
    [Abstract] [Full Text] [Related]

  • 2. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL.
    Cancer Lett; 2004 Jul 08; 210(1):101-9. PubMed ID: 15172127
    [Abstract] [Full Text] [Related]

  • 3. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G, Elsaleh H, McCaul K, Iacopetta B.
    J Pathol; 2001 Dec 08; 195(5):543-8. PubMed ID: 11745689
    [Abstract] [Full Text] [Related]

  • 4. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA.
    Br J Cancer; 2000 Aug 08; 83(4):473-9. PubMed ID: 10945494
    [Abstract] [Full Text] [Related]

  • 5. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY.
    Am Surg; 2005 Apr 08; 71(4):336-43. PubMed ID: 15943410
    [Abstract] [Full Text] [Related]

  • 6. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC, Lin JK, Lin TC, Liang WY.
    Int J Oncol; 2005 Jan 08; 26(1):65-75. PubMed ID: 15586226
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE, North Central Cancer Treatment Group.
    J Clin Oncol; 2004 May 01; 22(9):1572-82. PubMed ID: 15117979
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 9. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H, Levesque MA, Clark GM, Diamandis EP.
    Br J Cancer; 1999 Oct 01; 81(3):490-5. PubMed ID: 10507775
    [Abstract] [Full Text] [Related]

  • 10. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
    Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanese I, La Farina M, Tomasino RM, Gebbia N, Bazan V.
    Cancer Epidemiol Biomarkers Prev; 2002 Nov 01; 11(11):1322-31. PubMed ID: 12433709
    [Abstract] [Full Text] [Related]

  • 11. Clinical value of mitochondrial mutations in colorectal cancer.
    Lièvre A, Chapusot C, Bouvier AM, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P.
    J Clin Oncol; 2005 May 20; 23(15):3517-25. PubMed ID: 15908662
    [Abstract] [Full Text] [Related]

  • 12. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
    Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG.
    Cancer Res; 1997 May 01; 57(9):1769-75. PubMed ID: 9135021
    [Abstract] [Full Text] [Related]

  • 13. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.
    J Clin Oncol; 2005 Aug 20; 23(24):5635-43. PubMed ID: 16110022
    [Abstract] [Full Text] [Related]

  • 14. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS.
    J Clin Oncol; 2005 Mar 20; 23(9):1819-25. PubMed ID: 15774775
    [Abstract] [Full Text] [Related]

  • 15. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
    Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, Stephens LC.
    Clin Cancer Res; 1999 Jul 20; 5(7):1793-804. PubMed ID: 10430084
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
    Taal BG, Van Tinteren H, Zoetmulder FA, NACCP group.
    Br J Cancer; 2001 Nov 16; 85(10):1437-43. PubMed ID: 11720425
    [Abstract] [Full Text] [Related]

  • 17. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B.
    Clin Cancer Res; 2001 May 16; 7(5):1343-9. PubMed ID: 11350904
    [Abstract] [Full Text] [Related]

  • 18. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M, Adachi M, Huang C, Higashiyama M, Kodama K, Taki T.
    Oncogene; 1999 Apr 08; 18(14):2397-404. PubMed ID: 10327061
    [Abstract] [Full Text] [Related]

  • 19. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.
    J Clin Oncol; 2004 May 15; 22(10):1797-806. PubMed ID: 15067028
    [Abstract] [Full Text] [Related]

  • 20. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R, Sadikov E, Sulkes J, Klein B, Koren R.
    Dis Colon Rectum; 2004 Jul 15; 47(7):1216-24. PubMed ID: 15148649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.